

80.US2.ST25
SEQUENCE LISTING

<110> Jung, Jae-Kyu
Semple, Graeme
Johnson, Benjamin R

<120> 4-Oxo-4,5-dihydro-furan-2-carboxylic acid DERIVATIVES AND METHODS
OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF

<130> 80.US2.PCT

<150> 60/524,269

<151> 2003-11-21

<160> 2

<170> PatentIn version 3.2

<210> 1

<211> 1092

<212> DNA

<213> Homo sapien

<400> 1

atgaatcggc accatctgca ggatcacttt ctggaaatag acaagaagaa ctgctgtgtg	60
ttccgagatg acttcattgt caaggtgttg ccgccggtgt tggggctgga gtttatcttc	120
gggcttctgg gcaatggcct tgccctgtgg attttctgtt tccacctcaa gtcctggaaa	180
tccagccgga ttttcctgtt caacctggca gtggctgact ttctactgat catctgcctg	240
cccttcctga tggacaacta tgtgaggcgt tgggactgga agtttgggga catcccttgc	300
cggctgatgc tcttcatgtt ggctatgaac cgccagggca gcatcatctt cctcacggtg	360
gtggcggtag acaggatattt ccgggtgggtc catccccacc acgccctgaa caagatctcc	420
aatcggacag cagccatcat ctcttgcctt ctgtggggca tcactattgg cctgacagtc	480
cacctcctga agaagaagat gccgatccag aatggcggtg caaatattgtg cagcagcttc	540
agcatctgcc ataccttcca gtggcacgaa gccatgttcc tcctggagtt cttcctgccc	600
ctgggcatca tcctgttctg ctcagccaga attatctgga gcctgcggca gagacaaatg	660
gaccggcatg ccaagatcaa gagagccatc accttcatca tgggtggtggc catcgtcttt	720
gtcatctgct tccttcccag cgtgggtgtg cggatccgca tcttctggct cctgcacact	780
tcgggcacgc agaattgtga agtgtaccgc tcggtggacc tggcgttctt tatcactctc	840
agcttcacct acatgaacag catgctggac cccgtggtgt actacttctc cagcccatcc	900
tttcccaact tcttctccac tttgatcaac cgctgcctcc agaggaagat gacaggtgag	960
ccagataata accgcagcac gagcgtcgag ctcacagggg accccaacaa aaccagaggc	1020
gctccagagg cgttaatggc caactccggt gagccatgga gcccctctta tctgggccca	1080
acctctcctt aa	1092

80.US2.ST25

<210> 2
 <211> 363
 <212> PRT
 <213> Homo sapien

<400> 2

Met Asn Arg His His Leu Gln Asp His Phe Leu Glu Ile Asp Lys Lys
 1 5 10 15

Asn Cys Cys Val Phe Arg Asp Asp Phe Ile Val Lys Val Leu Pro Pro
 20 25 30

Val Leu Gly Leu Glu Phe Ile Phe Gly Leu Leu Gly Asn Gly Leu Ala
 35 40 45

Leu Trp Ile Phe Cys Phe His Leu Lys Ser Trp Lys Ser Ser Arg Ile
 50 55 60

Phe Leu Phe Asn Leu Ala Val Ala Asp Phe Leu Leu Ile Ile Cys Leu
 65 70 75 80

Pro Phe Leu Met Asp Asn Tyr Val Arg Arg Trp Asp Trp Lys Phe Gly
 85 90 95

Asp Ile Pro Cys Arg Leu Met Leu Phe Met Leu Ala Met Asn Arg Gln
 100 105 110

Gly Ser Ile Ile Phe Leu Thr Val Val Ala Val Asp Arg Tyr Phe Arg
 115 120 125

Val Val His Pro His His Ala Leu Asn Lys Ile Ser Asn Arg Thr Ala
 130 135 140

Ala Ile Ile Ser Cys Leu Leu Trp Gly Ile Thr Ile Gly Leu Thr Val
 145 150 155 160

His Leu Leu Lys Lys Lys Met Pro Ile Gln Asn Gly Gly Ala Asn Leu
 165 170 175

Cys Ser Ser Phe Ser Ile Cys His Thr Phe Gln Trp His Glu Ala Met
 180 185 190

Phe Leu Leu Glu Phe Phe Leu Pro Leu Gly Ile Ile Leu Phe Cys Ser
 195 200 205

Ala Arg Ile Ile Trp Ser Leu Arg Gln Arg Gln Met Asp Arg His Ala
 210 215 220

80.US2.ST25

Lys	Ile	Lys	Arg	Ala	Ile	Thr	Phe	Ile	Met	Val	Val	Ala	Ile	Val	Phe
225					230					235					240
Val	Ile	Cys	Phe	Leu	Pro	Ser	Val	Val	Val	Arg	Ile	Arg	Ile	Phe	Trp
				245					250					255	
Leu	Leu	His	Thr	Ser	Gly	Thr	Gln	Asn	Cys	Glu	Val	Tyr	Arg	Ser	Val
			260					265					270		
Asp	Leu	Ala	Phe	Phe	Ile	Thr	Leu	Ser	Phe	Thr	Tyr	Met	Asn	Ser	Met
		275					280					285			
Leu	Asp	Pro	Val	Val	Tyr	Tyr	Phe	Ser	Ser	Pro	Ser	Phe	Pro	Asn	Phe
	290					295					300				
Phe	Ser	Thr	Leu	Ile	Asn	Arg	Cys	Leu	Gln	Arg	Lys	Met	Thr	Gly	Glu
305					310					315					320
Pro	Asp	Asn	Asn	Arg	Ser	Thr	Ser	Val	Glu	Leu	Thr	Gly	Asp	Pro	Asn
				325					330					335	
Lys	Thr	Arg	Gly	Ala	Pro	Glu	Ala	Leu	Met	Ala	Asn	Ser	Gly	Glu	Pro
			340					345					350		
Trp	Ser	Pro	Ser	Tyr	Leu	Gly	Pro	Thr	Ser	Pro					
		355					360								